Kuhlencordt F, Ringe J D, Kruse H P
Dtsch Med Wochenschr. 1981 Nov 27;106(48):1620-3. doi: 10.1055/s-2008-1070566.
Subcutaneous injections for two days of 100 MRC units each of synthetic salmon calcitonin were administered to 40 out of 77 patients with Paget's disease of bone. Chemical pathology (alkaline serum phosphatase, hydroxyprolinuria) showed an initially satisfactory response of all patients to this treatment. Resistance developed in 6 out of 8 patients on long term treatment with recurrence of increased serum alkaline phosphatase, occurring after 4 months at the earliest and 24 months at the latest. Human calcitonin may be an alternative of treatment in these cases of secondary resistance. Treatment with calcitonin is nearly risk-free and represents a definite progress in comparison with earlier forms of treatment.
在77例骨Paget病患者中,40例接受了为期两天的皮下注射,每次注射100 MRC单位的合成鲑鱼降钙素。化学病理学(血清碱性磷酸酶、羟脯氨酸尿症)显示所有患者对该治疗最初反应良好。8例长期治疗的患者中有6例出现耐药,血清碱性磷酸酶再次升高,最早在4个月后出现,最晚在24个月后出现。在这些继发耐药的病例中,人降钙素可能是一种替代治疗方法。降钙素治疗几乎无风险,与早期治疗形式相比有明显进步。